Oncotelic Therapeutics Inc. (OTCQB: OTLC) is strategically positioning itself at the intersection of precision oncology, artificial intelligence, and advanced automation. The company is leveraging its PDAOAI artificial intelligence ecosystem, Deciparticle nanomedicine platform, and emerging robotics initiatives to build an integrated technology portfolio aimed at improving how therapies are developed, manufactured, and delivered for difficult-to-treat diseases.
A critical component of Oncotelic's strategy is the Deciparticle platform, developed through its relationship with Sapu Nano. This technology addresses longstanding challenges associated with hydrophobic drugs, which often suffer from poor solubility and limited bioavailability. By utilizing nanomedicine, the platform enhances drug delivery and therapeutic efficacy, particularly for cancer and rare diseases.
The company's PDAOAI ecosystem now incorporates 28 million scientific abstracts, providing a vast knowledge base for drug discovery and development. This AI-driven system is being deployed into real-world pharmaceutical automation applications through TechForce Robotics, enabling more efficient and precise processes in drug manufacturing and quality control.
Oncotelic's integrated approach aims to accelerate the development of therapies for conditions that have historically been difficult to treat. The combination of nanomedicine, AI, and robotics could streamline the entire therapeutic pipeline, from initial discovery through clinical trials to patient delivery. This may lead to faster approvals and improved outcomes for patients with cancer and rare diseases.
For more information on Oncotelic's latest updates, investors can visit the company's newsroom at ibn.fm/OTLC. Additional details about the PDAOAI ecosystem and its applications are available at ibn.fm/lU39h.
InvestorWire (IW), a specialized communications platform, distributed this press release. IW is part of the Dynamic Brand Portfolio @IBN, which offers wire-grade press release syndication, editorial syndication to over 5,000 outlets, and social media distribution. For more information, visit InvestorWire.com.
